Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

David
Strain
MD, University of Exeter Medical School, UK

Dr David Strain is a Senior Clinical Lecturer at the University of Exeter Medical School in the UK. He is an honorary consultant in medicine for the older adult, Head of the academic department for healthcare for older adults, and the co-chair of the British Medical Association’s medical academic staff committee. Clinically, he runs a community diabetes service for the older adult, works as an in-patient stroke consultant, and participates in the chronic fatigue service.

 

His main research focus is the health of older adults with diabetes and ensuring the right patient gets the right treatment. This includes research across the spectrum from mechanistic studies in the biologically young to pragmatic trials in the frail elderly population. He was the lead author on the UK guidance for the assessment and management of older adults with diabetes and frailty, which has recently led to a change in the NICE guidance and primary care contract.

 

He has performed the only study to date demonstrating the feasibility of individualizing targets for older adults across Europe and since March 2020, he has been heavily involved in the COVID-19 response team.